B+
Bull case
25%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-10-13 · RankAlpha Sentiment Codex
RDY
Dr Reddy's LaboratoriesBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Base-business growth and successful semaglutide supply recovery could improve margins; a timely abatacept approval would add a distinct biosimilar driver. These are conditional outcomes, not confirmed results.
Posture
Constructive
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-10-26.
What can break
FDA manufacturing or application queries could delay abatacept approval and launch. [#EARNINGS-TRANSCRIPT-2026Q1] Company transcript
Momentum
84
Value
64
Sentiment
49
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $13.40 · Bull $15.50 · Bear $10.20Analysis 2026-10-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $14.12
Why
Momentum84 · Δ7d -6.9
Value64 · Δ7d -0.3
Sentiment49 · Δ7d -0.9
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-10-26.
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • FDA manufacturing or application queries could delay abatacept approval and launch. [#EARNINGS-TRANSCRIPT-2026Q1] Company transcript
- • Lower lenalidomide sales and the semaglutide provision pressured Q1 FY27 revenue and margins. [#PR-EARNINGS-2026-07-22] Company earnings release
- • Q1 FY27 revenue fell 5.6% year over year and reported EBITDA margin was 12.5%; the company recorded a ₹2,397 million semaglutide API-related provision.
Catalyst clock
2026-11-30
Semaglutide supply recovery
Lead driver: Value · See fundamentals
Momentum
84
8% active weight
Current posture
7d trendFlat
Δ7d
-6.9
Δ21d
+15.5
Value
64
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-1.3
Sentiment
49
45% active weight
Current posture
7d trendFlat
Δ7d
-0.9
Δ21d
-
Why this grade
Composite grade B. Momentum 84.3 / Value 64.2 / Sentiment 48.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-13. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$13.40
Analysis reference price unavailable
Analysis 2026-10-13 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$10.20
Analysis reference price unavailable
Analysis 2026-10-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$11.42B
Beta
0.38
Shares Out
832.95M
P/E (TTM)
18.1
P/S (TTM)
3.03
P/FCF (TTM)
31.28
Rev YoY
-14.6%
EPS YoY
-71.7%
Gross Margin
+49.4%
Op Margin
+10.1%
Net Debt
-$110.42M
Current Ratio
1.90
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data